4 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 4 of 4 clinical reviews.
An evidence-based review of atorvastatin efficacy differences in Black and African ancestry patients, covering pharmacogenomics, ethnicity-stratified trial data, and clinical dosing considerations.
East Asian patients metabolize atorvastatin differently due to SLCO1B1 and ABCG2 transporter variants. This article reviews what pharmacokinetic and guideline evidence actually supports about lower starting doses, and where the evidence stops and clinical judgment begins.
East Asian patients taking atorvastatin (Lipitor) face distinct pharmacogenomic risks, different optimal starting doses, and ethnicity-specific myopathy thresholds. Here is what the clinical data says.
Atorvastatin dosing in Hispanic and Latino patients: ethnicity-stratified trial data, CYP3A4/SLCO1B1 pharmacogenomics, diabetes risk, and ACC/AHA guideline-concordant recommendations from the HealthRX.com medical team.